LEADERSHIP: James D. Rosener

Some recent transactions include:

  • the $900 million acquisition of one London Stock Exchange company in the health care industry by another London Stock Exchange Company. The target company had U.S. subsidiaries and U.S. shareholders.
  • the sale of stock of a Canadian software company to a publicly traded U.S. software company valued at $80 million
  • the sale of stock of two U.S. operating subsidiaries of a plastics/electronic components company listed on the London Stock Exchange for $50 million
  • the representation of a French company in its acquisition of a privately held U.S. yeast producer for $50 million
  • the acquisition of a Channel Island-based natural resources company for $45 million by a South African-based company
  • a French defense electronics company's $25 million acquisition of a U.S. space technology company
  • numerous acquisitions in the United States for a major French construction materials company
  • the $1.3 billion sale of a Nasdaq-listed bank to the U.S. subsidiary of a European bank holding company
  • the acquisition by merger of a Nasdaq-listed international telecommunications company for $140 million by another Nasdaq-listed international telecommunications company
  • the representation of a publicly traded provider of enterprise software and information technology services in its $34.5 million acquisition of a leading Dutch enterprise resource planning software company
  • the purchase by tender offer of a Canadian public company for $40 million
  • the purchase of a privately held malting plant from a Korean conglomerate for $37 million
  • the $20 million purchase of stock in a privately held Australian telecommunications company for cash and securities
  • the disposition of shares of a publicly traded U.S. electronics company by merger with a related publicly traded U.K. company involving registration of the securities to be sold.
  • a German pharmaceutical company in the purchase of a U.S. manufacturer of prescription and over-the-counter pharmaceutical products
  • an international pharmaceutical company in connection with its collaboration with a biotechnology company involving the joint development, manufacturing and marketing of a product designed to treat restenosis
  • a publicly held Australian biopharmaceutical company in several joint ventures with a group of Canadian companies.

Our international trade experience includes:

  • helping companies obtain commodity jurisdiction determinations and necessary export licenses; make voluntary disclosures of violations of the export control laws; respond to agency investigations of violations; and implement export control compliance programs 
  • assisting companies when goods have been excluded or seized by the Bureau of Customs and Border Protection under violations of customs laws or other U.S. laws, including negotiations over return of seized property 
  • assisting importers in determining the correct classification and country of origin marking of imported merchandise, preparing customs compliance programs and counseling importers during customs audits, including audits under NAFTA by all three signatory countries 
  • representing U.S. petitioners and foreign respondents in antidumping and countervailing duty actions before the U.S. Department of Commerce, the U.S. International Trade Commission, the U.S. Court of International Trade and NAFTA panels; representative industries include lumber, cement, sulfanilic acid, magnesium, manganese sulfate, cookware, automotive replacement glass windshields and red raspberries 
  • represented a leading manufacturer of gloves for the health care industry in a patent infringement suit and a related ITC Section 337 investigation concerning nitrile gloves 
  • representing domestic and foreign interests before the Office of the U.S. Trade Representative, the U.S. Congress and WTO panels involving Section 201 “Safeguard” actions, Section 301 and the Generalized System of Preferences; representative industries include steel, wheat gluten and rubber chemicals.

Data protection laws have changed, so we have revised our Privacy Policy.